1-trifluoromethyl-cyclobutanecarboxylic acid {1-[4-(4-fluoro-phenyl)-5-morpholin-4-yl-thiazol-2-ylcarbamoyl]-1-methyl-ethyl}-amide | 1205601-71-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-trifluoromethyl-cyclobutanecarboxylic acid {1-[4-(4-fluoro-phenyl)-5-morpholin-4-yl-thiazol-2-ylcarbamoyl]-1-methyl-ethyl}-amide
• 英文别名: N-[1-[[4-(4-fluorophenyl)-5-morpholin-4-yl-1,3-thiazol-2-yl]amino]-2-methyl-1-oxopropan-2-yl]-1-(trifluoromethyl)cyclobutane-1-carboxamide
• CAS: 1205601-71-3
• 化学式: C₂₃H₂₆F₄N₄O₃S
• 分子量: 514.544
• InChiKey: NOOPGYVMXKEDIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• ORGANIC COMPOUNDS
  申请人：Forster Cornelia Jutta

  公开号：US20100022513A1

  公开（公告）日：2010-01-28

  The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

  该发明涉及式(I)的化合物： 其中A是可选择取代的杂环烷基，用于治疗由酰基辅酶A-二酰基甘油酰基转移酶1（DGAT1）介导的疾病，例如代谢性疾病。该发明还提供了治疗这种疾病的方法，以及用于治疗的化合物和组合物等。
• Heteroaryl derivatives as DGAT1 inhibitors
  申请人：Novartis AG

  公开号：EP2380631A1

  公开（公告）日：2011-10-26

  The invention relates to compounds of formula (I): where A is a substituted thiazole or oxazole, useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

  本发明涉及式 (I) 化合物： 其中A为取代的噻唑或噁唑，可用于治疗由酰基辅酶A-二酰甘油酰基转移酶1（DGAT1）介导的疾病，如代谢紊乱。本发明还提供了治疗这类疾病的方法，以及治疗这类疾病的化合物和组合物等。
• HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS
  申请人：Novartis AG

  公开号：EP2349484A2

  公开（公告）日：2011-08-03
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2010007046A2

  公开（公告）日：2010-01-21

  The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA- diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.